

## Supporting Information

### *Epimerization-Free Access to C-Terminal Cysteine Peptide Acids, Carboxamides, Amides, and Esters via Complimentary Strategies*

Christine A. Arbour, Thilini D. Kondasinghe, Hasina Y. Saraha, Teanna L. Vorlicek and Jennifer  
L. Stockdill\*

*Department of Chemistry, Wayne State University, 5101 Cass Avenue, Detroit, MI 48202, United States*

#### Table of Contents

General Information.....	S2
Reagents and Materials .....	S2
Experimental Procedures and Spectroscopic Data (Cysteine Derivatives).....	S4
Experimental Procedures and Spectroscopic Data (Piperidine Epimerization).....	S6
Table 1, Evaluation of Cysteine Epimerization .....	S7
Scheme 2, Synthesis of $\alpha$ -Conotoxin Iml .....	S25
Table 2, C-terminal cysteine elongation on AWA-MeNbz .....	S31
Table 3, C-terminal cysteine elongation on various substrates .....	S44
Scheme 3, Synthesis of $\alpha$ -factor peptide .....	S51
$^1\text{H}$ and $^{13}\text{C}$ NMR Spectra .....	S53

**General Information.** Solid-Phase Peptide Synthesis was performed on a Biotage SP Wave Initiator<sup>+</sup> and all peptides were synthesized on either pre-loaded glycine Wang Resin (Fmoc-Gly-Wang Resin loading: 0.62 mmol/g from Chem-Impex Int'l. Inc.) or Rink Amide Resin (Novabiochem, 100-200 mesh, loading: 0.77 mmol/g). <sup>1</sup>H NMR spectra and <sup>13</sup>C NMR spectra were recorded on a Varian MR-400, Agilent MR-400, or a Varian V-500 MHz instrument with a multinuclear broadband probe at ambient temperature unless otherwise stated. Chemical shifts are reported in parts per million relative to residual solvent peaks (as established by Stoltz, et. Al. in *Organometallics* **2010**, 29, 2176). All <sup>13</sup>C spectra are recorded with complete proton decoupling. All HPLC analyses and purifications were performed on a Custom Reverse Phase Shimadzu Liquid Chromatograph Mass Spectrometer (LCMS-2020), which can toggle between analytical and semi-preparative columns. This instrument has a photodiode array (PDA) detector (D2 & W lamp), which collects a range of wavelengths, in place of a traditional single channel UV detector. RP-HPLC-MS mobile phases (MeCN and H<sub>2</sub>O) contained 0.1% Formic Acid. Analytical HPLC was performed on a Phenomenex Kinetex C18 column (5 μm, 250 x 4.6 mm) and a Thermo Scientific Hypersil Gold C8 column (5 μm, 250 x 4.6 mm). Semi-Preparative HPLC was conducted using a Thermo Scientific Hypersil Gold C8 column (5 μm, 150 x 10 mm). Thin layer chromatography was performed using glass-backed SiliaPlate™ TLC Plates (cat. # TLG-R10011B-323) cut to the desired size then visualized with short-wave UV lamps and KMnO<sub>4</sub>, CAM, PMA, or Anisaldehyde stains prepared according to standard recipes.<sup>1</sup> All yields refer to chromatographically and spectroscopically pure products. All peptide yields are calculated based on the final loading. Optical rotation data was collected on a Perkin-Elmer 341 automated Polarimeter at the concentration noted.

### Reagents and Materials.

Unless otherwise specified, all commercially available reagents were used without further purification. Anhydrous Et<sub>2</sub>O, PhMe, *n*-hexane, MeCN, DMF, DMSO, CH<sub>2</sub>Cl<sub>2</sub> were purchased from Fisher, THF was purchased from EMD, PhH was purchased from Sigma-Aldrich and HPLC grade MeCN and H<sub>2</sub>O were purchased from Fisher. These were passed through a commercial solvent purification system (2 columns of alumina) and used without further drying. Triethylamine, diisopropylamine, pyridine, and Hünig's base were distilled over CaH<sub>2</sub> immediately prior to use. All L- and D- amino acids were purchased from Chem-Impex Int'l. Inc. unless otherwise noted. HATU were purchased from Chem-Impex Int'l. Inc. 4-Nitrophenyl chloroformate was purchased from Alfa Aesar. 4-fluoro-3-nitrobenzoic acid, and *N*-(3-bromopropyl)phthalimide were purchased from Oakwood Chemical. 33 wt.% methylamine in absolute ethanol was purchased from Sigma-Aldrich. The authentic sample of α-Conotoxin Iml was obtained free of charge from Alomone Labs.

<sup>1</sup> Leonard, J.; Lygo, B.; Procter, G. In *Advanced Practical Organic Chemistry*; CRC Press: Boca Raton, FL, 2013; pp 158. (ISBN: 978-1-4398-6097-7)

**SPPS.**

All substrates were made on either pre-loaded Gly-Wang Resin or Rink Amide Resin on a 500 mg scale (loadings varied).

**Semi-Automated Microwave Synthesis of Peptides:**

- *Reactor Vials [Vial size (Volume range allowed)]*: 2 mL reactor vial (0.8-1.1 mL), 5 mL reactor vial (1.6-3.2 mL), and 10 mL reactor vial (3.2-6.4 mL)
- *Swell + Heat*: DMF was added and vortexed at 1200 RPM for 20 min at 70 °C. The solvent was then removed over 1 m followed by two DMF washes (DMF was added and the suspension was vortexed at 600 RPM for 45 s, followed by the removal of solvent (over 2 min)).
- *Coupling*: A solution of Fmoc-aa-OH (5 equiv), HATU (4.9 equiv), and DIEA (10 equiv) in DMF was made immediately prior to addition to the reaction vial containing the resin. Once the solution was added, the suspension was heated to 75 °C for 5 min with a vortex rate of 1200 RPM. After the reaction, the solution was removed (over 2 min) and the resin was rinsed with DMF 4 times (after addition of DMF, the suspension was agitated at a vortex rate of 1200 RPM for 1 min, solvent removal was at a rate of 2 m). Fmoc-Cys(Trt)-OH was coupled using a *modified* method established by Dawson, P. E. *JACS* **2015**, to minimize epimerization, using Fmoc-Cys-OH (1.55 mmol), HATU (1.55 mmol), DIEA (1.705 mmol) in 4 mL DMF at 75 °C for 5 min.<sup>2</sup>
- *Fmoc Removal (Deprotection)*: The reactor vial was filled with 20% piperidine in DMF. The suspension was vortexed at 1200 RPM for 3 min at RT. The solvent is removed followed by addition of 20% piperidine in DMF. The suspension is vortexed again at 1200 RPM for 10 min at RT. The solvent was removed over 2 min, followed by 4 DMF washes (after addition of DMF, the suspension was agitated at a vortex rate of 1200 RPM for 1 min, solvent removal was at a rate of 2 min).
- *Wash*: DMF was added to the reaction vial and agitated at a vortex rate of 1200 RPM for 1 min. The solvent was removed over 1 min and repeated for a total of 4 times.
- *Final Wash*: Resin was rinsed with CH<sub>2</sub>Cl<sub>2</sub> (3 x 1 mL) and MeOH (3 x 1 mL).
- *Drying for Storage/Weighing*: After the final wash, the resin was placed on the lyophilizer overnight for drying.

**Native Chemical Ligation Buffer:**

The buffer was made using a previously established protocol.<sup>3</sup>

**MeDbz activation:**


Activation conditions were conducted using a previously established protocol.<sup>2</sup>

<sup>2</sup> Blanco-Canosa, J. B.; Nardone, B.; Albericio, F.; Dawson, P. E. *J. Am. Chem. Soc.* **2015**, *137*, 7197–7209.

<sup>3</sup> Aussedat, B.; Fasching, B.; Johnston, E.; Sane, N.; Nagorny, P.; Danishefsky, S. J. *J. Am. Chem. Soc.* **2012**, *134*, 3532–3541.

### Calculating *Conversion* of On Resin Reactions.


After the nucleophilic cleavage was conducted, the resin was subjected to 95:2.5:2.5 TFA:TIPS:H<sub>2</sub>O to cleave the remaining *MeNbz-Gly* and unreacted peptide-*MeNbz-Gly*. The solvent was concentrated using a constant stream of air until a small amount of residue was left. Then cold diethyl ether was added to the vial to crash out the crude peptide. After centrifugation, the ether was decanted off and the solid was dissolved in 1:1 MeCN:H<sub>2</sub>O and lyophilized. The lyophilized solid was then dissolved in 20% MeCN/H<sub>2</sub>O and analyzed via RP-HPLC-MS using a gradient of 20-80% MeCN/H<sub>2</sub>O over 15 min. Conversion was calculated based on the ratio of H<sub>2</sub>N-peptide-*MeNbz-Gly*-OH<sup>4</sup> to H<sub>2</sub>N-*MeNbz-Gly*-OH.



### Synthesis of cysteine amide.

1 g (2.76 mmol) of H-Cys(Trt)-NH<sub>2</sub> was weighed out into a 100 mL round bottom flask containing a stir bar. The amino acid was then dissolved in 10 mL of (49:50:1) CH<sub>2</sub>Cl<sub>2</sub>:TFA:TIPS and stirred at ambient temperature. After 15 min, TIPS was added dropwise until the solution turned from bright red-orange to a pale yellow solution. The volatile solvent was then removed under reduced pressure after 30 min, followed by addition of 40 mL water. A white solid was filtered off and the filtrate was frozen (LN<sub>2</sub>), and lyophilized to yield the crude cysteine amide in >99% yield (745 mg). <sup>1</sup>H NMR (499 MHz, Acetonitrile-*d*<sub>3</sub>) δ 7.16 (s, 1H), 6.68 (s, 1H), 4.20 (t, *J* = 5.3 Hz, 1H), 3.06 (qd, *J* = 14.9, 5.1 Hz, 2H). <sup>13</sup>C NMR (126 MHz, CD<sub>3</sub>CN) δ 169.8, 55.3, 26.0.


<sup>4</sup> In some cases, Fmoc was still intact and incorporated into the % conversion calculation.



### Synthesis of cysteine butylamide.

**Step 1 (Synthesis Boc-Cys(Trt)-NHBu):** To a microwave vial was added Boc-Cys(Trt)-OH and HATU (plus stir bar) and the vial was sealed with a cap. Thereafter, DMF was added and the reagents were fully dissolved. Upon completion of the reagents dissolving, butylamine was added (vial felt warm). Then, the vial was placed in the microwave for 5.5 mins at 75 °C. This was done two times, and the reaction was monitored by direct MS. Unfortunately, the reaction did not go to completion after these two rounds of microwaving. The reaction was allowed to stir vigorously for 2 days at ambient temperature. Again, the starting material was observed. The reaction was then quenched/diluted with water (white precipitate). Then, ethyl acetate was added. A clear line was not achievable between the aqueous and organic layer. Therefore, brine was added and the extraction solution (aqueous) became clear, and it was obvious where the layers sectioned for extraction. The aqueous layer was extracted 5 times, and the organic layer was dried over sodium sulfate. After filtration, the organic layer was concentrated and purified using column chromatography (DCM to 5% MeOH/DCM). 243.2 mg (43% yield).  $^1H$  NMR (400 MHz, Chloroform- $d$ )  $\delta$  7.42 (d,  $J$  = 7.4 Hz, 6H), 7.28 (t,  $J$  = 7.5 Hz, 6H), 7.21 (t,  $J$  = 7.2 Hz, 3H), 6.05 (s, 1H), 4.94-4.84 (bs, 1H), 3.95-3.74 (bs, 1H), 3.17 (q,  $J$  = 6.7 Hz, 2H), 2.69 (dd,  $J$  = 12.5, 7.0 Hz, 1H), 2.52 (dd,  $J$  = 12.8, 5.4 Hz, 1H), 1.41 (s, 10H), 1.29 (m, 2H), 0.88 (t,  $J$  = 7.3 Hz, 3H).  $^{13}C$  NMR (101 MHz,  $CDCl_3$ )  $\delta$  170.29, 155.37, 144.44, 129.57, 128.02, 126.83, 80.14, 67.13, 53.62, 39.18, 33.91, 31.43, 28.27, 19.94, 13.71.


**Step 2 (Synthesis SI-04):** To a round bottom flask containing Boc-Cys(Trt)-NHBu, 40 mL of deprotection cocktail (49:50:1 of DCM:TFA:TIS) was added to dissolve the residue, and the deprotection was carried out for 30 minutes at room temperature. The solvent was removed under vacuum, and the residue was suspended in 20 mL of water, and then filtered. The filtrate was collected. Thereafter, the aqueous layer was rinsed once with hexanes. The hexanes was discarded, and the aqueous layer was frozen using liquid nitrogen and lyophilized. 142.3 mg (>99% yield).  $^1H$  NMR (400 MHz, Methanol- $d_4$ )  $\delta$  3.98 – 3.91 (m, 1H), 3.32 – 3.17 (m, 3H), 3.05 – 2.89 (m, 2H), 1.57 – 1.47 (m, 2H), 1.38 (dd,  $J$  = 15.1, 7.3 Hz, 3H), 0.94 (t,  $J$  = 7.3 Hz, 3H).  $^{13}C$  NMR (101 MHz,  $CD_3OD$ )  $\delta$  166.75, 54.74, 39.02, 30.92, 24.89, 19.62, 12.58.  $[\alpha]_D^{25}$  +5.05 (c 1.01, MeOH).




**Figure SI-1.** A) Co-injection, B) D-Cys, C) L-Cys made from AWC-MeNbz-Gly-Rink, and D) L-Cys from AW-MeNbz-Gly-Rink, gradient: 20-40% MeCN/ $H_2O$  + 1%  $HCOOH$  over 15 min.<sup>5</sup>

<sup>5</sup> The cysteine butylamide was used to displace AW-MeNbz-Gly-Rink to generate AWC-NHBu (**6a-NHBu**). This allowed us to confirm its enantiopurity.


## Experimental Procedures and Spectroscopic Data (Piperidine Epimerization)




Peptide **SI-05** was synthesized using a standard Fmoc-SPPS protocol described on S3. Both D- and L-Cys(Trt) substrates were made.<sup>2</sup>



**Figure SI-2.** A) L-Cys, B) D-Cys, and C) Co-injection after SPPS, gradient: 40-95% MeCN/H<sub>2</sub>O + 1% HCOOH over 15 min. \*Note: The indicated peak in the above spectra is a side product of Trp(Boc) in TFA.<sup>6</sup>




10 mg of resin was weighed out into a 2 mL reactor vial and swelled in CH<sub>2</sub>Cl<sub>2</sub> for 30 min. After this time the solvent was removed and the resin was subjected to 20% piperidine in DMF for 2, 4, & 24 h. Then the solvent was removed and the resin was rinsed with DMF (3 x 1 mL) and CH<sub>2</sub>Cl<sub>2</sub> (3 x 1 mL). The resin was then subjected to 95:2.5:2.5 TFA:TIPS:H<sub>2</sub>O for 0.5 h. The solvent was collected after this time and concentrated under a constant stream of air. The sample was then crashed out with cold diethyl ether, centrifuged, and decanted to yield the crude peptide. The peptide was dissolved in 50% MeCN:H<sub>2</sub>O and analyzed via RP-HPLC-MS using a gradient of 20% MeCN:H<sub>2</sub>O over 15 min.




**Figure SI-3.** A) L-Cys after 24 h, B) 4 h, C) 2 h, and D) co-injection, gradient: 40-95% MeCN/H<sub>2</sub>O + 1% HCOOH over 15 min.

<sup>6</sup> Franzén, H.; Grehn, L.; Ragnarsson, U. *J. Chem. Soc., Chem. Commun.* **1984**, 0, 1699–1700.


**Table 1. Evaluation of cysteine epimerization.**

**Table 1, Entry 1:  $H_2N$ -AWC- $NH_2$  (6a- $NH_2$ ).** 100 mg of peptide on resin (dry) was weighed out into a 5 mL fritted reaction vial with an attached needle and rubber stopper. The resin was swelled in  $CH_2Cl_2$  (500  $\mu$ L – 4 mL) for 30 min. The MeDbz linker was activated by a previously established protocol.<sup>2,7</sup> Next, 500  $\mu$ L of DMF was added and the reaction vial was closed off with a septum (needle and stopper still attached at the bottom). A double balloon was made and filled with ammonia. A hypodermic needle was attached to the balloon and inserted into the septum and submerged into the DMF solution. The smallest (blue) gauge needle was placed into the septum to allow for the slow exiting of gas. The ammonia gas was bubbled into DMF for 1.5 h. Then the solvent was removed and collected. Additional rinsing was required to completely remove the desired peptide from resin.  $CH_2Cl_2$  (3 x 1 mL) was used to rinse the resin, followed by MeCN (3 x 1 mL), and lastly  $CH_2Cl_2$  (3 x 1 mL). The washes were combined with the initial DMF solution, blown down with air, subjected to 1:1 MeCN:H<sub>2</sub>O, frozen (LN<sub>2</sub>), and lyophilized to yield the crude product. Purification was conducted after 3 cycles of lyophilization (until crude product composition was a fluffy white solid). A silica column was used with a mobile phase eluent of 50-100% MeCN/Ethyl Acetate followed by 0-10% MeOH/ $CH_2Cl_2$ . The product was isolated, concentrated under reduced pressure, and lyophilized to yield a fluffy white solid (11.56 mg, 54%). <sup>1</sup>H NMR (499 MHz, DMSO-*d*<sub>6</sub>)  $\delta$  8.37 (d, *J* = 8.2 Hz, 1H), 8.16 (s, 1H), 8.01 (d, *J* = 8.1 Hz, 1H), 7.64 (d, *J* = 7.8 Hz, 1H), 7.45 (s, 1H), 7.39 – 7.18 (m, 19H), 7.16 (s, 1H), 4.64 (s, 1H), 4.32 (q, *J* = 6.9 Hz, 1H), 3.26 (q, *J* = 6.9 Hz, 2H), 3.12 (dd, *J* = 14.7, 4.1 Hz, 1H), 2.98 – 2.88 (m, 1H), 2.37 (d, *J* = 6.7 Hz, 2H), 1.60 (s, 9H), 1.02 (d, *J* = 6.9 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO)  $\delta$  171.8, 171.1, 168.6, 144.7, 144.2, 129.5, 128.5, 127.2, 124.7, 124.5, 122.9, 122.8, 119.9, 116.7, 108.5, 83.9, 66.2, 52.2, 51.9, 50.6, 34.5, 31.2, 28.2, 27.8, 21.4.




**Figure SI-4.** Analytical Column PDA of purified peptide at 190 nm. Gradient: 40-95% MeCN/H<sub>2</sub>O + 1% HCOOH over 15 min. Retention time: 8.77 min.

<sup>7</sup> Blanco-Canosa, J. B.; Dawson, P. E. *Angew. Chem. Int. Ed.* **2008**, 47, 6851–6855.




**Figure SI-5.** Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H<sub>2</sub>O + 1% HCOOH over 15 min.




**Figure SI-6.** A) D-Cys, B) L-Cys, and C) Co-injection, gradient: 40-70% MeCN/H<sub>2</sub>O + 1% HCOOH over 15 min.







**Table 1, Entry 2: H<sub>2</sub>N-AWC-NHBn (6a-NHBn).** 20 mg of resin (**5a**) was weighed out into a 2 mL reactor vial and swelled in CH<sub>2</sub>Cl<sub>2</sub> for 15 min. After this time the solvent was removed and the resin was subjected to activation conditions. Then 200  $\mu$ L of BnNH<sub>2</sub> was added to the resin and agitated for 1.5 h at ambient temperature. The solvent was then removed and immediately subjected to 3 mL of TFA:TIPS:H<sub>2</sub>O (95:2.5:2.5) and agitated for 30 min. After this time, the solvent was blown down with a constant stream of air, dissolved in 1:1 MeCN:H<sub>2</sub>O, frozen (LN<sub>2</sub>), and lyophilized to yield the crude peptide. Then 2 mL of TFA:TIPS:H<sub>2</sub>O (95:2.5:2.5) was added to the crude peptide solid and agitated for 1 h. The solvent was blown down with a constant stream of air, crashed out with cold diethyl ether, centrifuged, decanted and the solid was dissolved in 20% MeCN:H<sub>2</sub>O (1% TFA) and analyzed via RP-HPLC-MS.




**Figure SI-7.** A) L-Cys, B) D-Cys, and C) Co-injection, gradient: 20-40% MeCN/H<sub>2</sub>O + 1% HCOOH over 15 min.




**Figure SI-8.** Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H<sub>2</sub>O + 1% HCOOH over 15 min.




**Table 1, Entry 3: H<sub>2</sub>N-AWC-NHBn (6a-NHBn).** 20 mg of resin (**5a**) was weighed out into a 2 mL reactor vial and swelled in CH<sub>2</sub>Cl<sub>2</sub> for 15 min. After this time the solvent was removed and the resin was subjected to activation conditions. Then 200  $\mu$ L MeCN was added to the resin followed by 5 equiv BnNH<sub>2</sub> and agitated for 1.5 h at ambient temperature. The solvent was then removed and immediately subjected to 0.5 mL of TFA:TIPS:H<sub>2</sub>O (95:2.5:2.5). After this time, the solvent was concentrated down, dissolved in 1:1 MeCN:H<sub>2</sub>O, frozen (LN<sub>2</sub>), and lyophilized to yield the crude peptide. Then 2 mL of TFA:TIPS:H<sub>2</sub>O (95:2.5:2.5) was added to the crude peptide solid and agitated for 1 h. The solvent was blown down with a constant stream of air, crashed out with cold diethyl ether, centrifuged, decanted and the solid was dissolved in 20% MeCN:H<sub>2</sub>O (1% TFA) and analyzed via RP-HPLC-MS.



**Figure SI-9.** A) Co-injection and B) L-Cys, gradient: 20-40% MeCN/H<sub>2</sub>O + 1% HCOOH over 15 min.




**Figure SI-10.** Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H<sub>2</sub>O + 1% HCOOH over 15 min.




**Table 1, Entry 4: H<sub>2</sub>N-AWC-NHBu (6a-NHBu).** 20 mg of resin (5a) was weighed out into a 2 mL reactor vial and swelled in CH<sub>2</sub>Cl<sub>2</sub> for 15 min. After this time the solvent was removed and the resin was subjected to activation conditions. Then 200  $\mu$ L of BuNH<sub>2</sub> was added to the resin and agitated for 1.5 h at ambient temperature. The solvent was then removed and immediately subjected to 3 mL of TFA:TIPS:H<sub>2</sub>O (95:2.5:2.5) and agitated for 30 min. After this time, the solvent was blown down with a constant stream of air, dissolved in 1:1 MeCN:H<sub>2</sub>O, frozen (LN<sub>2</sub>), and lyophilized to yield the crude peptide. Then 2 mL of TFA:TIPS:H<sub>2</sub>O (95:2.5:2.5) was added to the crude peptide solid and agitated for 1 h. The solvent was blown down with a constant stream of air, crashed out with cold diethyl ether, centrifuged, decanted and the solid was dissolved in 20% MeCN:H<sub>2</sub>O (1% TFA) and analyzed via RP-HPLC-MS.


MS Chromatogram(CAA-VII-057-47\_coinject\_20-40-15m\_C18-3.7.lcd,  
CAA-VII-057-20-40-15m\_C18-3.6\_2.lcd, CAA-VII-047\_20-40-15m\_C18\_3.6.lcd)  
(x1,000)




**Figure SI-11.** A) Co-injection and B) L-Cys, gradient: 20-40% MeCN/H<sub>2</sub>O + 1% HCOOH over 15 min.




**Figure SI-12.** Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H<sub>2</sub>O + 1% HCOOH over 15 min.




**Table 1, Entry 5: AWC-NHBu (6a-NHBu).** 20 mg of resin (**5a**) was weighed out into a 2 mL reactor vial and swelled in  $\text{CH}_2\text{Cl}_2$  for 15 min. After this time the solvent was removed and the resin was subjected to activation conditions. Then 10 equiv butylamine in 200  $\mu\text{L}$  DMF was added to the resin and agitated for 1.5 h at ambient temperature. The solvent was then removed and immediately subjected to 0.5 mL of TFA:TIPS: $\text{H}_2\text{O}$  (95:2.5:2.5). After this time, the solvent was concentrated down, dissolved in 1:1 MeCN: $\text{H}_2\text{O}$ , frozen ( $\text{LN}_2$ ), and lyophilized to yield the crude peptide. Then 2 mL of TFA:TIPS: $\text{H}_2\text{O}$  (95:2.5:2.5) was added to the crude peptide solid and agitated for 1 h. The solvent was blown down with a constant stream of air, crashed out with cold diethyl ether, centrifuged, decanted and the solid was dissolved in 20% MeCN: $\text{H}_2\text{O}$  (1% TFA) and analyzed via RP-HPLC-MS.




**Figure SI-13.** A) Co-injection and B) L-Cys, using a gradient of 20-40% MeCN/ $\text{H}_2\text{O}$  + 1%  $\text{HCOOH}$  over 15 min.




**Figure SI-14.** Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/ $\text{H}_2\text{O}$  + 1%  $\text{HCOOH}$  over 15 min.




**Table 1, Entry 6: AWC-NHBu (6a-NHBu).** 20 mg of resin (**5a**) was weighed out into a 2 mL reactor vial and swelled in CH<sub>2</sub>Cl<sub>2</sub> for 15 min. After this time the solvent was removed and the resin was subjected to activation conditions. Then 200  $\mu$ L of MeCN and added to the resin followed by 5 equiv butylamine. The resin was agitated for 1.5 h at ambient temperature. The solvent was then removed and immediately subjected to 0.5 mL of TFA:TIPS:H<sub>2</sub>O (95:2.5:2.5). After this time, the solvent was concentrated down, dissolved in 1:1 MeCN:H<sub>2</sub>O, frozen (LN<sub>2</sub>), and lyophilized to yield the crude peptide. Then 2 mL of TFA:TIPS:H<sub>2</sub>O (95:2.5:2.5) was added to the crude peptide solid and agitated for 1 h. The solvent was blown down with a constant stream of air, crashed out with cold diethyl ether, centrifuged, decanted and the solid was dissolved in 20% MeCN:H<sub>2</sub>O (1% TFA) and analyzed via RP-HPLC-MS.




**Figure SI-15.** A) Co-injection, B) D-Cys, and C) L-Cys, using a gradient of 20-40% MeCN/H<sub>2</sub>O + 1% HCOOH over 15 min.




**Figure SI-16.** Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H<sub>2</sub>O + 1% HCOOH over 15 min.




**Table 1, Entry 7: AWC-NHBu (6a-NHBu).** 20 mg of resin (**5a**) was weighed out into a 2 mL reactor vial and swelled in CH<sub>2</sub>Cl<sub>2</sub> for 15 min. After this time the solvent was removed and the resin was subjected to activation conditions. Then 200  $\mu$ L of MeCN and added to the resin followed by 1.1 equiv butylamine. The resin was agitated for 1.5 h at ambient temperature. The solvent was then removed and immediately subjected to 0.5 mL of TFA:TIPS:H<sub>2</sub>O (95:2.5:2.5). After this time, the solvent was concentrated down, dissolved in 1:1 MeCN:H<sub>2</sub>O, frozen (LN<sub>2</sub>), and lyophilized to yield the crude peptide. Then 2 mL of TFA:TIPS:H<sub>2</sub>O (95:2.5:2.5) was added to the crude peptide solid and agitated for 1 h. The solvent was blown down with a constant stream of air, crashed out with cold diethyl ether, centrifuged, decanted and the solid was dissolved in 20% MeCN:H<sub>2</sub>O (1% TFA) and analyzed via RP-HPLC-MS.




**Figure SI-17.** A) Co-injection, B) D-Cys, and C) L-Cys, gradient of 20-40% MeCN/H<sub>2</sub>O + 1% HCOOH over 15 min.




**Figure SI-18.** Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H<sub>2</sub>O + 1% HCOOH over 15 min.



**Table 1, Entry 8: AWC(Acm)-NHBu (6b-NHBu).** 20 mg of resin (**5b**) was weighed out into a 2 mL reactor vial and swelled in  $\text{CH}_2\text{Cl}_2$  for 15 min. After this time the solvent was removed and the resin was subjected to activation conditions. Then 200  $\mu\text{L}$  of MeCN and added to the resin followed by 5 equiv butylamine. The resin was agitated for 1.5 h at ambient temperature. The solvent was then removed and immediately subjected to 0.5 mL of TFA:TIPS: $\text{H}_2\text{O}$  (95:2.5:2.5). After this time, the solvent was concentrated down, dissolved in 1:1 MeCN: $\text{H}_2\text{O}$ , frozen ( $\text{LN}_2$ ), and lyophilized to yield the crude peptide. Then 2 mL of TFA:TIPS: $\text{H}_2\text{O}$  (95:2.5:2.5) was added to the crude peptide solid and agitated for 1 h. The solvent was blown down with a constant stream of air, crashed out with cold diethyl ether, centrifuged, decanted and the solid was dissolved in 20% MeCN: $\text{H}_2\text{O}$  (1% TFA) and analyzed via RP-HPLC-MS.




**Figure SI-19.** A) L-Cys, B) D-Cys, and C) co-injection gradient of 20-45-95% MeCN/ $\text{H}_2\text{O}$  + 1%  $\text{HCOOH}$  over 15 min.




**Figure SI-20.** Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/ $\text{H}_2\text{O}$  + 1%  $\text{HCOOH}$  over 15 min.






**Table 1, Entry 9: AWC(Mob)-NHBu (6c-NHBu).** 20 mg of resin (**5c**) was weighed out into a 2 mL reactor vial and swelled in  $\text{CH}_2\text{Cl}_2$  for 15 min. After this time the solvent was removed and the resin was subjected to activation conditions. Then 200  $\mu\text{L}$  of MeCN and added to the resin followed by 5 equiv butylamine. The resin was agitated for 1.5 h at ambient temperature. The solvent was then removed and immediately subjected to 0.5 mL of TFA:TIPS:H<sub>2</sub>O (95:2.5:2.5). After this time, the solvent was concentrated down, dissolved in 1:1 MeCN:H<sub>2</sub>O, frozen (LN<sub>2</sub>), and lyophilized to yield the crude peptide. Then 2 mL of TFA:TIPS:H<sub>2</sub>O (95:2.5:2.5) was added to the crude peptide solid and agitated for 1 h. The solvent was blown down with a constant stream of air, crashed out with cold diethyl ether, centrifuged, decanted and the solid was dissolved in 20% MeCN:H<sub>2</sub>O (1% TFA) and analyzed via RP-HPLC-MS.




**Figure SI-021.** A) Co-injection, B) L-Cys, using a gradient of 30% MeCN/H<sub>2</sub>O + 1% HCOOH over 15 min, PDA: 254 nm.




**Figure SI-22.** Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H<sub>2</sub>O + 1% HCOOH over 15 min.







**Table 1, Entry 10: AWC(Bzl)-NHBu (6d-NHBu).** 20 mg of resin (**5d**) was weighed out into a 2 mL reactor vial and swelled in  $CH_2Cl_2$  for 15 min. After this time the solvent was removed and the resin was subjected to activation conditions. Then 200  $\mu$ L of MeCN and added to the resin followed by 5 equiv butylamine. The resin was agitated for 1.5 h at ambient temperature. The solvent was then removed and immediately subjected to 0.5 mL of TFA:TIPS:H<sub>2</sub>O (95:2.5:2.5). After this time, the solvent was concentrated down, dissolved in 1:1 MeCN:H<sub>2</sub>O, frozen (LN<sub>2</sub>), and lyophilized to yield the crude peptide. Then 2 mL of TFA:TIPS:H<sub>2</sub>O (95:2.5:2.5) was added to the crude peptide solid and agitated for 1 h. The solvent was blown down with a constant stream of air, crashed out with cold diethyl ether, centrifuged, decanted and the solid was dissolved in 20% MeCN:H<sub>2</sub>O (1% TFA) and analyzed via RP-HPLC-MS.




**Figure SI-23.** A) Co-injection, B) D-Cys, and C) L-Cys, gradient of 30% MeCN/H<sub>2</sub>O + 1% HCOOH over 15 min, PDA: 254 nm.




**Figure SI-24.** Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H<sub>2</sub>O + 1% HCOOH over 15 min.




**Table 1, Entry 11: AWC-NHBu (6a-NHBu).** 20 mg of resin (**5e**) was weighed out into a 2 mL reactor vial and swelled in  $\text{CH}_2\text{Cl}_2$  for 15 min. After this time the solvent was removed and the resin was subjected to activation conditions. Then 200  $\mu\text{L}$  of MeCN was added to the resin followed by 5 equiv butylamine. The resin was agitated for 1.5 h at ambient temperature. The solvent was then removed and immediately subjected to 0.5 mL of TFA:TIPS: $\text{H}_2\text{O}$  (95:2.5:2.5). After quenching, the solvent was concentrated down, dissolved in 1:1 MeCN: $\text{H}_2\text{O}$ , frozen ( $\text{LN}_2$ ), and lyophilized to yield the crude peptide. Then 2 mL of TFA:TIPS: $\text{H}_2\text{O}$  (95:2.5:2.5) was added to the crude peptide solid and stirred for 1 h to give the deprotected cystine peptide (**AWC(StBu)-NHBu**, **6e-NHBu**). The solvent was blown down with a constant stream of air, crashed out with cold diethyl ether, centrifuged, decanted, and the solid was dissolved in 500  $\mu\text{L}$  TFE and stirred at ambient temperature with 5 equiv  $\text{Bu}_3\text{P}$  for 2 h. After this time, the solvent was concentrated under a constant stream of air, suspended in  $\text{H}_2\text{O}$ , frozen ( $\text{LN}_2$ ), and lyophilized to yield the crude peptide. The peptide was dissolved in 20% MeCN: $\text{H}_2\text{O}$  (1% TFA) and analyzed via RP-HPLC-MS.




**Figure SI-25.** A) L-Cys and B) Co-injection, gradient of 20-40% MeCN/ $\text{H}_2\text{O}$  + 1%  $\text{HCOOH}$  over 15 min.




**Figure SI-26.** Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/ $\text{H}_2\text{O}$  + 1%  $\text{HCOOH}$  over 15 min.




**Table 1, Entry 12: AWC(*t*Bu)-NHBu (6f-NHBu).** 20 mg of resin (**5f**) was weighed out into a 2 mL reactor vial and swelled in  $\text{CH}_2\text{Cl}_2$  for 15 min. After this time the solvent was removed and the resin was subjected to activation conditions. Then 200  $\mu\text{L}$  of MeCN and added to the resin followed by 5 equiv butylamine. The resin was agitated for 1.5 h at ambient temperature. The solvent was then removed and immediately subjected to 0.5 mL of TFA:TIPS: $\text{H}_2\text{O}$  (95:2.5:2.5). After this time, the solvent was concentrated down, dissolved in 1:1 MeCN: $\text{H}_2\text{O}$ , frozen ( $\text{LN}_2$ ), and lyophilized to yield the crude peptide. Then 2 mL of TFA:TIPS: $\text{H}_2\text{O}$  (95:2.5:2.5) was added to the crude peptide solid and agitated for 1 h. The solvent was blown down with a constant stream of air, crashed out with cold diethyl ether, centrifuged, decanted and the solid was dissolved in 20% MeCN: $\text{H}_2\text{O}$  (1% TFA) and analyzed via RP-HPLC-MS.




**Figure SI-27.** A) Co-injection, B) D-Cys, and C) L-Cys, gradient of 20-40% MeCN/ $\text{H}_2\text{O}$  over 15 min.




**Figure SI-28.** Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/ $\text{H}_2\text{O}$  + 1%  $\text{HCOOH}$  over 15 min.




**Table 1, Entry 13: AWC-OMe (6a-OMe).** 20 mg of resin (**5a**) was weighed out into a 2 mL reactor vial and swelled in  $CH_2Cl_2$  for 15 min. After this time the solvent was removed and the resin was subjected to activation conditions. Then 0.7 equiv  $KOtBu$  was dissolved in 200  $\mu L$  of MeOH and added to the resin. The resin was agitated for 1.5 h at ambient temperature. The solvent was then removed and immediately subjected to 0.5 mL of TFA:TIPS:H<sub>2</sub>O (95:2.5:2.5). After this time, the solvent was concentrated down, dissolved in 1:1 MeCN:H<sub>2</sub>O, frozen (LN<sub>2</sub>), and lyophilized to yield the crude peptide. Then 2 mL of TFA:TIPS:H<sub>2</sub>O (95:2.5:2.5) was added to the crude peptide solid and agitated for 1 h. The solvent was blown down with a constant stream of air, crashed out with cold diethyl ether, centrifuged, decanted and the solid was dissolved in 20% MeCN:H<sub>2</sub>O (1% TFA) and analyzed via RP-HPLC-MS.




**Figure SI-29.** A) L-Cys after  $KOtBu$  treatment and B) L-Cys reference, using a gradient of 20-20(12 min)-95%(3 min) MeCN/H<sub>2</sub>O + 1% HCOOH over 15 min.




**Figure SI-30.** Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H<sub>2</sub>O + 1% HCOOH over 15 min.



**Table 1, Entry 14: AWC-OMe (6a-OMe).** 20 mg of resin (**5g**) was weighed out into a 2 mL reactor vial and swelled in  $\text{CH}_2\text{Cl}_2$  for 15 min. After this time the solvent was removed and the resin was subjected to activation conditions. Then 200  $\mu\text{L}$  of MeOH was added to the resin followed by 5 equiv DIEA. The resin was agitated for 3 h at ambient temperature. The solvent was then removed and immediately subjected to 0.5 mL of TFA:TIPS:H<sub>2</sub>O (95:2.5:2.5). After this time, the solvent was concentrated down, dissolved in 1:1 MeCN:H<sub>2</sub>O, frozen ( $\text{LN}_2$ ), and lyophilized to yield the crude peptide. Then 2 mL of TFA:TIPS:H<sub>2</sub>O (95:2.5:2.5) was added to the crude peptide solid and agitated for 1 h. The solvent was blown down with a constant stream of air, crashed out with cold diethyl ether, centrifuged, decanted and the solid was dissolved in 20% MeCN:H<sub>2</sub>O (1% TFA) and analyzed via RP-HPLC-MS.




**Figure SI-31.** Gradient of 20-20(12 min)-95%(3 min) MeCN:H<sub>2</sub>O + 1% HCOOH over 15 min.<sup>8</sup>




**Figure SI-32.** Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H<sub>2</sub>O + 1% HCOOH over 15 min.


<sup>8</sup> The L-Cys substrate has a delayed elution in the assay, but since no second peak is observed we reported no detectable epimerization.




**Table 1, Entry 15: AWC-OMe (6a-OMe).** 20 mg of resin (**5g**) was weighed out into a 2 mL reactor vial and swelled in CH<sub>2</sub>Cl<sub>2</sub> for 15 min. After this time the solvent was removed and the resin was subjected to activation conditions. Then 200  $\mu$ L of MeOH was added to the resin along with 200  $\mu$ L of Na<sub>2</sub>HPO<sub>4</sub>/NaH<sub>2</sub>PO<sub>4</sub> buffer at pH = 8. The resin was agitated for 1.5 h at ambient temperature. The solvent was then removed and immediately subjected to 0.5 mL of TFA:TIPS:H<sub>2</sub>O (95:2.5:2.5). After this time, the solvent was frozen (LN<sub>2</sub>), and lyophilized to yield the crude peptide. Then 2 mL of TFA:TIPS:H<sub>2</sub>O (95:2.5:2.5) was added to the crude peptide solid and agitated for 1 h. The solvent was blown down with a constant stream of air, crashed out with cold diethyl ether, centrifuged, decanted and the solid was dissolved in 20% MeCN:H<sub>2</sub>O (1% TFA) and analyzed via RP-HPLC-MS.




**Figure SI-33.** Gradient of 20-20(12 min)-95(3 min) MeCN:H<sub>2</sub>O + 1% HCOOH over 15 min.




**Figure SI-34.** Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H<sub>2</sub>O + 1% HCOOH over 15 min.



**Table 1, Entry 16: AWC-OH (6a-OH).** 20 mg of resin (**5g**) was weighed out into a 2 mL reactor vial and swelled in  $\text{CH}_2\text{Cl}_2$  for 15 min. After this time the solvent was removed and the resin was subjected to activation conditions. Then 200  $\mu\text{L}$  of (1:1)  $\text{H}_2\text{O}/\text{MeCN}$  was added to the resin followed by 5 equiv DIEA. The resin was agitated for 1.5 h at ambient temperature. The solvent was then removed and immediately subjected to 0.5 mL of TFA:TIPS: $\text{H}_2\text{O}$  (95:2.5:2.5). After this time, the solvent was frozen ( $\text{LN}_2$ ), and lyophilized to yield the crude peptide. Then 2 mL of TFA:TIPS: $\text{H}_2\text{O}$  (95:2.5:2.5) was added to the crude peptide solid and agitated for 1 h. The solvent was blown down with a constant stream of air, crashed out with cold diethyl ether, centrifuged, decanted and the solid was dissolved in 20%  $\text{MeCN}:\text{H}_2\text{O}$  (1% TFA) and analyzed via RP-HPLC-MS.




**Figure SI-35.** A) Co-injection and B) L-Cys, Gradient of 20%  $\text{MeCN}:\text{H}_2\text{O}$  + 1%  $\text{HCOOH}$  over 15 min.




**Figure SI-36.** Analytical Column PDA for determination of conversion. Gradient: 20-80%  $\text{MeCN}/\text{H}_2\text{O}$  + 1%  $\text{HCOOH}$  over 15 min.






**Table 1, Entry SI-01: AWC-OH (6a-OH).** 20 mg of resin (**5g**) was weighed out into a 2 mL reactor vial and swelled in  $\text{CH}_2\text{Cl}_2$  for 15 min. After this time the solvent was removed and the resin was subjected to activation conditions. Then 200  $\mu\text{L}$  of (1:1)  $\text{H}_2\text{O}/\text{MeCN}$  was added to the resin followed by 5 equiv DIEA. The resin was agitated for 18 h at ambient temperature. The solvent was then removed and immediately subjected to 0.5 mL of TFA:TIPS: $\text{H}_2\text{O}$  (95:2.5:2.5). After this time, the solvent was frozen ( $\text{LN}_2$ ), and lyophilized to yield the crude peptide. Then 2 mL of TFA:TIPS: $\text{H}_2\text{O}$  (95:2.5:2.5) was added to the crude peptide solid and agitated for 1 h. The solvent was blown down with a constant stream of air, crashed out with cold diethyl ether, centrifuged, decanted and the solid was dissolved in 20% MeCN: $\text{H}_2\text{O}$  (1% TFA) and analyzed via RP-HPLC-MS.




**Figure SI-37.** A) Co-injection and B) L-Cys, Gradient of 20% MeCN: $\text{H}_2\text{O}$  + 1%  $\text{HCOOH}$  over 15 min.




**Figure SI-38.** Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/ $\text{H}_2\text{O}$  + 1%  $\text{HCOOH}$  over 15 min.



**Scheme 2. Synthesis of  $\alpha$ -Conotoxin lml.**

100 mg (24  $\mu\text{mol}$ ) of peptide **7** was weighed out into a 5 mL fritted peptide vial and swelled in  $\text{CH}_2\text{Cl}_2$  for 15 min. The solvent was removed and the peptide was activated (See MeDbz activation). Next, 500  $\mu\text{L}$  of DMF was added and the reaction vial was closed off with a septum (needle and stopper still attached at the bottom). A double balloon was made and filled with ammonia. A hypodermic needle was attached to the balloon and inserted into the septum and submerged into the DMF solution. The smallest (blue) gauge needle was placed into the septum to allow for the slow exiting of gas. The ammonia gas was bubbled into DMF for 1.5 h. Then the solvent was removed and collected. Additional rinsing was required to completely remove the desired peptide from resin.  $\text{CH}_2\text{Cl}_2$  (3 x 1 mL) was used to rinse the resin, followed by MeCN (3 x 1 mL), and lastly  $\text{CH}_2\text{Cl}_2$  (3 x 1 mL). The washes were combined with the initial DMF solution, blown down with air, subjected to 1:1 MeCN: $\text{H}_2\text{O}$ , frozen ( $\text{LN}_2$ ), and lyophilized to yield the crude product (70% crude yield, 86% HPLC purity). The crude peptide was then fully deprotected using TFA:TIPS: $\text{H}_2\text{O}$  (95:2.5:2.5) for 1.5 h. The solvent was blown down, crashed out with cold diethyl ether, centrifuged, and the ether was decanted off to yield the crude fully deprotected peptide. The solid was dissolved in 1:1 MeCN: $\text{H}_2\text{O}$ , frozen ( $\text{LN}_2$ ), and lyophilized. The peptide was purified by RP-HPLC-MS to yield the reduced peptide in 25% yield (8.9 mg).



**Figure SI-39.** Analytical Column PDA of crude peptide **8**, gradient of 5-30% MeCN/ $\text{H}_2\text{O}$  + 1%  $\text{HCOOH}$  over 15 min.







Figure SI-40. Analytical Column PDA of pure peptide 8, gradient of 5-40% MeCN/H<sub>2</sub>O + 1% HCOOH over 15 min.




8.6 mg (5.7  $\mu\text{mol}$ ) of **8** was dissolved in 6 mL  $\text{Na}_2\text{HPO}_4/\text{NaH}_2\text{PO}_4$  buffer (that was previously adjusted to pH 8 with 5 M NaOH). Then 60  $\mu\text{L}$  of DMSO was added to the mixture and allowed to stir overnight at ambient temperature. After complete consumption of starting material, which was monitored by RP-HPLC-MS, peptide **9** was further oxidized (see next scheme) without removal from this reaction mixture.




**Figure SI-41.** Analytical Column PDA of crude peptide **9** at 254 nm, gradient of 5-20% MeCN/ $\text{H}_2\text{O}$  + 1%  $\text{HCOOH}$  over 15 min.




The solution of peptide **9**, in the previously mentioned buffer, was subjected to 8 equiv iodine in a solution of (4:1) MeOH:H<sub>2</sub>O (the MeOH/H<sub>2</sub>O mixture was added until the iodine was completely dissolved). The removal of AcM and final folding was monitored by RP-HPLC-MS. After complete consumption of starting material, the mixture was quenched with ascorbic acid. The solid ascorbic acid was added portion-wise until the red solution turned clear. The mixture was then frozen (LN<sub>2</sub>), and lyophilized to yield the crude peptide **10**. The peptide was purified using RP-HPLC-MS to yield the pure peptide in 52% yield (4.2 mg).



**Figure SI-42.** Analytical Column PDA illustrating the final folding step of  $\alpha$ -conotoxin lml, gradient of 5-20% MeCN/H<sub>2</sub>O + 1% HCOOH over 15 min.




**Figure SI-43.** Analytical Column PDA of pure peptide **10**, gradient of 5-20% MeCN/H<sub>2</sub>O + 1% HCOOH over 15 min. Retention time: 13.84 min.




**Figure SI-44.** A) Analytical Column PDA of commercial  $\alpha$ -conotoxin ImI at 254 nm, B) co-injection of synthetic (solution-phase folding) and commercial sample, gradient of 5-40% MeCN/H<sub>2</sub>O + 1% HCOOH over 15 min.


### On-resin folding then activation/cleavage of $\alpha$ -conotoxin ImI




80.0 mg (19.2  $\mu$ mol) of **7** was swelled in DMF for 30 min. Then 2.0 mL solution of I<sub>2</sub> (5 equiv, 40.6 mg) in CH<sub>2</sub>Cl<sub>2</sub> was added to the resin and allowed to agitate for 90 min at ambient temperature. Next, the reaction mixture was filtered and the resin was washed thoroughly with CH<sub>2</sub>Cl<sub>2</sub> (10 x 1 mL) and DMF (10 x 1 mL). The peptide was activated (See MeDbz activation). Then, 500  $\mu$ L of DMF was added and the reaction vial was closed off with a septum (needle and stopper still attached at the bottom). A double balloon was made and filled with ammonia. A hypodermic needle was attached to the balloon and inserted into the septum and submerged into the DMF solution. The smallest (blue) gauge needle was placed into the septum to allow for the slow exiting of gas. The ammonia gas was bubbled into DMF for 2.0 h. Then the solvent was removed and collected. Additional rinsing was required to completely remove the desired peptide from resin. CH<sub>2</sub>Cl<sub>2</sub> (3 x 1 mL) was used to rinse the resin, followed by MeCN (3 x 1 mL), and lastly CH<sub>2</sub>Cl<sub>2</sub> (3 x 1 mL). The washes were combined with the initial DMF solution, blown down with air, subjected to 1:1 MeCN:H<sub>2</sub>O, frozen (LN<sub>2</sub>), and lyophilized. The resulting crude peptide was then fully deprotected using TFA:TIPS:H<sub>2</sub>O (95:2.5:2.5) for 2.0 h. The solvent was blown down, crashed out with cold diethyl ether, centrifuged, and the ether was decanted off to yield the crude fully deprotected peptide **10**. The solid was dissolved in 1:1 MeCN:H<sub>2</sub>O, frozen (LN<sub>2</sub>), and lyophilized. The peptide was purified by RP-HPLC-MS to afford a mixture of conotoxins foldamers in 43% yield (11.2 mg).




**Figure SI-45.** Analytical Column PDA of pure peptide **10** at 254 nm, gradient of 5-40% MeCN/H<sub>2</sub>O + 1% HCOOH over 15 min. Retention time: 9.08 min.




**Figure SI-46.** A) Analytical Column PDA of commercial  $\alpha$ -conotoxin ImI at 254 nm, B) co-injection, C) synthetic sample, gradient of 5-40% MeCN/H<sub>2</sub>O + 1% HCOOH over 15 min.

**Table 2. On-Resin C-Terminal Ligation.**


**Table 2, Entry 1:** 20 mg of **12** was weighed out into a 2 mL reaction vial and swelled in 500  $\mu$ L  $CH_2Cl_2$  for 30 min. After swelling the solvent was removed and the linker was activated. 10 equiv of H-Cys-OH·HCl was dissolved in 500  $\mu$ L DMF and 100  $\mu$ L  $H_2O$  in a separate vial and added to the swelled resin. Then 11 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. The solvent was removed from the vial and quenched in (1% TFA) 20% MeCN/ $H_2O$ . The resin was further rinsed with  $CH_2Cl_2$  (3 x 1 mL) and combined with the initial solvent. The volatile solvent was blown down and the remaining solution was frozen in liquid nitrogen, and lyophilized to yield the crude peptide **14a**.

**Figure SI-47.** Analytical Column PDA of crude peptide at 254 nm. Gradient: 40-95-95% MeCN/ $H_2O$  + 1%  $HCOOH$ .




**Figure SI-48.** Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H<sub>2</sub>O + 1% HCOOH over 15 min.







**Table 2, Entry 2:** 20 mg of **12** was weighed out into a 2 mL reaction vial and swelled in 500  $\mu$ L  $CH_2Cl_2$  for 30 min. After swelling the solvent was removed and the linker was activated. 10 equiv of H-Cys-OEt·HCl was dissolved in 500  $\mu$ L DMF and added to the swelled resin. Then 11 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. The solvent was removed from the vial and quenched in (1% TFA) 20% MeCN/ $H_2O$ . The resin was further rinsed with  $CH_2Cl_2$  (3 x 1 mL) and combined with the initial solvent. The volatile solvent was blown down and the remaining solution was frozen in liquid nitrogen, and lyophilized to yield the crude peptide **14b**.




**Figure SI-49.** Analytical Column PDA of crude peptide at 254 nm. Gradient: 40-95-95% MeCN/ $H_2O$  + 1% HCOOH. Retention time: 9.00 min.




**Figure SI-50.** Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H<sub>2</sub>O + 1% HCOOH over 15 min.




**Table 2, Entry 3:** 20 mg of **12** was weighed out into a 2 mL reaction vial and swelled in 500  $\mu$ L  $CH_2Cl_2$  for 30 min. After swelling the solvent was removed and the linker was activated. 10 equiv of H-Cys-NH<sub>2</sub>•TFA was dissolved in 500  $\mu$ L DMF and added to the swelled resin. Then 11 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. The solvent was removed from the vial and quenched in (1% TFA) 20% MeCN/H<sub>2</sub>O. The resin was further rinsed with  $CH_2Cl_2$  (3 x 1 mL) and combined with the initial solvent. The volatile solvent was blown down and the remaining solution was frozen in liquid nitrogen, and lyophilized to yield the crude peptide **14c**.




**Figure SI-51.** Analytical Column PDA of crude peptide at 254 nm. Gradient: 40-95-95% MeCN/H<sub>2</sub>O + 1% HCOOH. Retention time: 7.80 min.




**Figure SI-52.** Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H<sub>2</sub>O + 1% HCOOH over 15 min.




**Table 2, Entry 4:** 20 mg of **12** was weighed out into a 5 mL reaction vial and swelled in 500  $\mu$ L  $CH_2Cl_2$  for 30 min. After swelling the solvent was removed and the linker was activated. 10 equiv of H-Cys-NHBu was dissolved in 500  $\mu$ L DMF and added to the swelled resin. Then 11 equiv of DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. The solvent was removed from the vial and quenched in 20% MeCN/ $H_2O$  (1% TFA). The resin was further rinsed with  $CH_2Cl_2$  (3 x 1 mL) and combined with the initial solvent. The volatile solvent was blown down and the remaining solution was frozen in liquid nitrogen, and lyophilized to yield the crude peptide **SI-06**.




**Figure SI-53.** Analytical Column PDA of crude peptide at 254 nm. Gradient: 40-95-95% MeCN/ $H_2O$  + 1%  $HCOOH$ . Retention time: 6.24 min.




**Figure SI-054.** Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H<sub>2</sub>O over 15 min.<sup>6</sup>




**Table 2, Entry 5:** 10 equiv H-Cys-OH·HCl was weighed out into a vial containing a stir bar. 20 mg of crude peptide (**13**) was dissolved in 200  $\mu$ L of HPLC grade MeCN and 100  $\mu$ L H<sub>2</sub>O and added to the amino acid containing vial. 11 equiv of freshly distilled DIEA was added to the vial and allowed to stir at ambient temperature for 30 min. After 30 min, the reactions were quenched in 20% MeCN/H<sub>2</sub>O (1% TFA) and analyzed via RP-HPLC-MS.




**Figure SI-55.** Reaction progress after 30 min of H-Cys-OH addition, Gradient: 20-45(12 min)-95(3 min)% MeCN/H<sub>2</sub>O + 1% HCOOH over 15 min.



**Table 2, Entry 6:** 10 equiv H-Cys-OEt was weighed out into a vial containing a stir bar. 20 mg of crude peptide (**13**) was dissolved in 200  $\mu$ L of HPLC grade MeCN and added to the amino acid containing vial. 11 equiv of freshly distilled DIEA was added to the vial and allowed to stir at ambient temperature for 30 min. After 30 min, the reactions were quenched in 20% MeCN/H<sub>2</sub>O (1% TFA) and analyzed via RP-HPLC-MS.




**Figure SI-56.** Reaction progress after 30 min of H-Cys-OEt addition, Gradient: 20-45(12 min)-95(3 min)% MeCN/H<sub>2</sub>O + 1% HCOOH over 15 min.




**Figure SI-57.** A) Co-injection, B) D-Cys, and C) L-Cys of in solution elongation of Cys-OEt, Gradient: 20-20(10 min)-45(5 min)% MeCN/H<sub>2</sub>O + 1% HCOOH over 15 min.







**Table 2, Entry 7:** 10 equiv H-Cys-NH<sub>2</sub> was weighed out into a vial containing a stir bar. 20 mg of crude peptide (**13**) was dissolved in 200  $\mu\text{L}$  of HPLC grade MeCN and added to the amino acid containing vial. 11 equiv of freshly distilled DIEA was added to the vial and allowed to stir at ambient temperature for 30 min. After 30 min, the reactions were quenched in 20% MeCN/H<sub>2</sub>O (1% TFA) and analyzed via RP-HPLC-MS.




**Figure SI-58.** Reaction progress after 30 min of H-Cys-NH<sub>2</sub> addition, Gradient: 20-45(12 min)-95(3 min)% MeCN/H<sub>2</sub>O + 1% HCOOH over 15 min.




**Table 2, Entry 8:** 10 equiv H-Cys-NHBu was weighed out into a vial containing a stir bar. 3.8 mg of crude peptide (13) was dissolved in 500  $\mu$ L of HPLC grade MeCN and 20  $\mu$ L H<sub>2</sub>O and added to the amino acid containing vial. 11 equiv of freshly distilled DIEA was added to the vial and allowed to stir at ambient temperature for 30 min. After 30 min, the reactions were quenched in 20% MeCN/H<sub>2</sub>O (1% TFA) and analyzed via RP-HPLC-MS.




**Figure SI-59.** Reaction progress after 30 min of H-Cys-NH<sub>2</sub> addition, Gradient: 20-80% MeCN/H<sub>2</sub>O + 1% HCOOH over 15 min.

**Co-injection of C-terminal Cys-OH elongation and authentic sample.**


**Figure SI-60. A)** Co-injection of authentic sample and elongated product, **B)** C-terminal Cys-OH elongated product, AWAC-OH, gradient: 20-45(12 min)-95(3 min)% MeCN/H<sub>2</sub>O + 1% HCOOH over 15 min.

**Table 3. Cysteine elongation to generate C-terminal acids, carboxamides, and esters.**


**Table 3, entry 1.** 20 mg of peptide **15b** (24.8  $\mu$ mol) was dissolved in 600  $\mu$ L of (5:1) MeCN:H<sub>2</sub>O. 39 mg of H-Cys-OH·HCl (10 equiv, 0.25 mmol) was weighed out into a vial containing a stir bar. The solution of peptide was transferred to the vial containing the amino acid, followed by addition of 48  $\mu$ L DIEA (11 equiv, 0.27 mmol). The mixture was stirred at ambient temperature for 30 min. The reaction was quenched with 20% MeCN/H<sub>2</sub>O (1% TFA) and analyzed via RP-HPLC-MS.




**Figure SI-61.** Reaction progress after 30 min of H-Cys-OH addition, Gradient: 20-45(12 min)-95(3 min)% MeCN/H<sub>2</sub>O + 1% HCOOH over 15 min.




**Table 3, entry 2.** 20 mg of peptide **16a** (7  $\mu$ mol) was swelled in  $CH_2Cl_2$  for 30 min. After swelling the solvent was removed and the peptide was activated. In a separate vial, 8.5 mg of H-Cys-OH $\cdot$ HCl (10 equiv, 70  $\mu$ mol) was dissolved in 500  $\mu$ L (1:1) DMF:NCL buffer followed by the addition of 13  $\mu$ L DIEA (11 equiv, 77  $\mu$ mol). The solution of the amino acid was transferred to the resin and agitated at ambient temperature for 4 h. The reaction was quenched with 20% MeCN/ $H_2O$  (1% TFA) and analyzed via RP-HPLC-MS.




**Figure SI-62.** Analytical Column PDA of crude peptide **16c**, gradient of 40-95-95% MeCN/ $H_2O$  + 1% HCOOH over 15 min.




**Figure SI-63.** Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/ $H_2O$  + 1% HCOOH over 15 min.




**Table 3, entry 3.** 10 mg of peptide **16b** (11  $\mu\text{mol}$ ) was dissolved in 250  $\mu\text{L}$  of NCL buffer. 17.5 mg of H-Cys-OH $\cdot$ HCl (10 equiv, 0.11 mmol) was weighed out into a vial containing a stir bar. The solution of peptide was transferred to the vial containing the amino acid, followed by addition of 21  $\mu\text{L}$  DIEA (11 equiv, 0.12 mmol). The mixture was stirred at ambient temperature for 1 h. The reaction was quenched with 20% MeCN/ $\text{H}_2\text{O}$  (1% TFA) and analyzed via RP-HPLC-MS.




**Figure SI-64.** Analytical Column PDA of crude peptide **16c** after 1 h, gradient of 40-95-95% MeCN/ $\text{H}_2\text{O}$  + 1%  $\text{HCOOH}$  over 15 min.



**Table 3, entry 4.** 20 mg of peptide **17a** (7 μmol) was swelled in CH<sub>2</sub>Cl<sub>2</sub> for 30 min. After swelling the solvent was removed and the peptide was activated. In a separate vial, 8.4 mg of H-Cys-NH<sub>2</sub>·TFA (10 equiv, 70 μmol) was dissolved in 500 μL (1:1) DMF:NCL buffer followed by the addition of 13 μL DIEA (11 equiv, 77 μmol). The solution of the amino acid was transferred to the resin and agitated at ambient temperature for 4 h. The reaction was quenched with 20% MeCN/H<sub>2</sub>O (1% TFA) and analyzed via RP-HPLC-MS. Due to the protected peptide adhering to the resin, the resin was rinsed with TFA:TIPS:H<sub>2</sub>O (95:2.5:2.5), collected, blown down under a constant stream of air, crashed out with cold diethyl ether, centrifuged, and decanted to yield the deprotected peptide which was analyzed via RP-HPLC-MS.




**Figure SI-65.** Analytical Column PDA of crude peptide **17c**, gradient of 40-95-95% MeCN/H<sub>2</sub>O + 1% HCOOH over 15 min.




**Figure SI-66.** Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H<sub>2</sub>O + 1% HCOOH over 15 min.







**Table 3, entry 5.** 20 mg of peptide **18a** (7  $\mu$ mol) was swelled in  $\text{CH}_2\text{Cl}_2$  for 30 min. After swelling the solvent was removed and the peptide was activated. In a separate vial, 12 mg of H-Cys OMe $\cdot$ HCl (10 equiv, 70  $\mu$ mol) was dissolved in 500  $\mu$ L (1:1) DMF:NCL buffer followed by the addition of 13  $\mu$ L DIEA (11 equiv, 77  $\mu$ mol). The solution of the amino acid was transferred to the resin and agitated at ambient temperature for 4 h. The reaction was quenched with 20% MeCN/ $\text{H}_2\text{O}$  (1% TFA) and analyzed via RP-HPLC-MS. Due to the protected peptide adhering to the resin, the resin was rinsed with TFA:TIPS: $\text{H}_2\text{O}$  (95:2.5:2.5), collected, blown down under a constant stream of air, crashed out with cold diethyl ether, centrifuged, and decanted to yield the deprotected peptide which was analyzed via RP-HPLC-MS. *However, product was not observed.*




**Figure SI-067.** Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H<sub>2</sub>O + 1% HCOOH over 15 min.




**Table 3, entry 6.** 67.3 mg of crude peptide **18b** (87  $\mu\text{mol}$ ) was dissolved in 250  $\mu\text{L}$  of NCL buffer. 149 mg of H-Cys-OMe $\cdot$ HCl (10 equiv, 0.87 mmol) was weighed out into a vial containing a stir bar. The solution of peptide was transferred to the vial containing the amino acid, followed by addition of 167  $\mu\text{L}$  DIEA (11 equiv, 0.96 mmol). The mixture was stirred at ambient temperature for 30 min. The reaction was quenched with 20% MeCN/H<sub>2</sub>O (1% TFA) and analyzed via RP-HPLC-MS.




**Figure SI-68.** Reaction progress after 30 min of H-Cys-OMe addition, Gradient: 20-80% MeCN/H<sub>2</sub>O + 1% HCOOH over 15 min, Retention time: 5.98 min.

**Scheme 3. Synthesis of  $\alpha$ -factor peptide 21.**


50 mg (12  $\mu$ mol) of peptide **19** was activated (See MeDbz activation) and suspended in a pre-mixed solution of (10 equiv) H-Cys-OMe•HCl and (11 equiv) DIEA in (1:1) DMF:NCL buffer (pH 7.2). The mixture was agitated for 4 h at ambient temperature. The solvent was removed and collected. The resin was rinsed with CH<sub>2</sub>Cl<sub>2</sub> (2 x), water (2 x), followed by (1:1:3) TFE:AcOH:CH<sub>2</sub>Cl<sub>2</sub> (2 x). The rinses were combined with the initial reaction solvent, blown down under a constant stream of air, diluted with water, frozen (LN<sub>2</sub>), and lyophilized to yield the fully protected crude peptide. Some remaining peptide was adhered to the resin, which was removed using 95:2.5:2.5 TFA:TIPS:H<sub>2</sub>O rinses and combined with the following residue. The fully protected peptide residue was dissolved in (95:2.5:2.5) TFA:TIPS:H<sub>2</sub>O and agitated for 1.5 h. The solvent was concentrated down under a constant stream of air, crashed out with cold diethyl ether, centrifuged, decanted off, and the solid was dissolved in 1:1 MeCN:H<sub>2</sub>O, frozen (LN<sub>2</sub>), and lyophilized. The crude deprotected peptide was then dissolved in 10% THF/H<sub>2</sub>O (800  $\mu$ L) and sparged with argon for 15 min. 5 equiv of Bu<sub>3</sub>P was added to the solution and stirred at ambient temperature for 2 h. The volatile solvent was removed under reduced pressure and the aqueous solution was frozen (LN<sub>2</sub>) and lyophilized. The solid was purified using RP-HPLC-MS to yield the non-alkylated  $\alpha$ -factor precursor **20** in 41% yield (7.0 mg).




**Figure SI-69.** Analytical Column PDA of pure peptide **21**, gradient of 20-70% MeCN/H<sub>2</sub>O + 1% HCOOH over 15 min. Retention time: 7.75 min.




**Figure SI-70.** Analytical Column PDA for determination of conversion. Gradient: 20-80% MeCN/H<sub>2</sub>O over 15 min.





2 mg (1.4  $\mu$ mol) of H-YIIKGVFWDPAC-OMe **20** was weighed out in a 25 mL round bottom flask and dissolved in 0.8 mL DMF/BuOH (2:1). Then 5 equiv of Fr-Br (2.0 mg, 7.0  $\mu$ mol) was added to the solution followed by a solution of 5 equiv Zn(OAc)<sub>2</sub> (1.3 mg, 7.0  $\mu$ mol) in 0.4 mL 0.1% TFA (aq). The reaction went to completion after 1 h followed by dilution with H<sub>2</sub>O, frozen in LN<sub>2</sub>, and lyophilized to yield the crude peptide. RP-HPLC-MS purification was conducted resulting in a 9% yield of farnesylated  $\alpha$ -factor peptide **21** (0.2 mg).




**Figure SI-71.** Analytical Column PDA of pure peptide at 190 nm. Gradient: 20-70% + 1% HCOOH MeCN/H<sub>2</sub>O.


$^1\text{H}$  and  $^{13}\text{C}$  SpectraCAA-VII-094\_MeCN\_1H  
std proton


CAA-VII-094\_MeCN\_13C  
standard carbon








HYS-IX-016\_MeOH  
Proton





CAH-IV-066\_pure\_13C  
standard carbon